Vaz-Luis I, Ottesen RA, Hughes ME, Marcom PK, Moy B, Rugo HS, Theriault RL, Wilson J, Niland JC, Weeks JC, Lin NU: Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study.
Breast Cancer Res 2012, 14:R129. PubMed?Abstract | BioMed?Central?Full?Text
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
Lancet 2005, 365:1687-1717. PubMed?Abstract | Publisher?Full?Text
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Lancet 2011, 378:771-784. PubMed?Abstract | Publisher?Full?Text | PubMed?Central?Full?Text
Genentech Inc. Herceptin ? (trastuzumab). US Prescribing information [online] [http://www.gene.com/gene/products/information/pdf/herceptin-prescribing.pdf] webcite
San Francisco, CA: Genentech Inc; 2008.
Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, Flynn PJ, Ingle JN, Visscher D, Jenkins RB: HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.
J Clin Oncol 2006, 24:3032-3038. PubMed?Abstract | Publisher?Full?Text
Perez EA, Romond EH, Suman VJ, Jeong J-H, Davidson NE, Geyer CE, Martino S, Mamounas EP, Kaufman PA, Wolmark N: Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-postive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
J Clin Oncol 2011, 29:3366-3373. PubMed?Abstract | Publisher?Full?Text | PubMed?Central?Full?Text
Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zujewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB: Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.
J Clin Oncol 2011, 29:4491-4497. PubMed?Abstract | Publisher?Full?Text | PubMed?Central?Full?Text
Perez EA, Dueck AC, McCullough AE, Reinholz MM, Tenner KS, Davidson NE, Gralow J, Harris LN, Kutteh LA, Hillman DW, Jenkins RB, Chen B: Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.
J Natl Cancer Inst 2012, 104:159-162. PubMed?Abstract | Publisher?Full?Text
Gluck S, Arteaga CL, Osborne CK: Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient.
Clin Cancer Res 2011, 17:5559-5561. PubMed?Abstract | Publisher?Full?Text
Romond EH, Suman VJ, Jeong J, Sledge GW, Geyer C, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, et al.: Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831.
Cancer Res 2012, 72(suppl 24):S5-5.
Goldhirsch A, Piccart-Gebhart MJ, Procter M, de Azambuja E, Weber HA, Untch M, Smith I, Gianni L, Jackisch C, Cameron D, Bell R, Dowsett M, Gelber RD, Leyland-Jones B, Baselga J, the HERA Study Team: HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up.
Cancer Res 2012, 72(suppl 24):S5-2.
Sun Z, Asmann YW, Kalari KR, Bot B, Eckel-Passow JE, Baker TR, Carr JM, Khrebtukova I, Luo S, Zhang L, Schroth GP, Perez EA, Thompson EA: Integrated analysis of gene expression, CpG island methylation, and gene copy number in breast cancer cells by deep sequencing.
PLoS One 2011, 6:e17490. PubMed?Abstract | Publisher?Full?Text | PubMed?Central?Full?Text
Asmann YW, Necela BM, Kalari KR, Hossain A, Baker TR, Carr JM, Davis C, Getz JE, Hostetter G, Li X, McLaughlin SA, Radisky DC, Schroth GP, Cunliffe HE, Perez EA, Thompson EA: Detection of redundant fusion transcripts as biomarkers or disease-specific therapeutic targets in breast cancer.
Cancer Res 2012, 72:1921-1928. PubMed?Abstract | Publisher?Full?Text
Perez EA, Eckel-Passow JE, Ballman KV, Anderson S, Thompson EA, Asmann YW, Jen J, Dueck AC, Lingle WL, Sledge GW, et al.: Predictive genomic markers to chemotherapy and adjuvant trastuzumab via whole genome expression DASL profiling in the N9831 adjuvant study.
Cancer Res 2012, 72(suppl 24):PD10-04.
Crozier JA, Moreno-Aspitia A, Ballman KV, Martino S, Kutteh LA, Davidson NE, Kaufman PA, Perez EA: Correlation between BMI and clinical outcome of patients with early stage HER2+ breast cancer from the N9831 clinical trial.
Cancer Res 2011, 71(Suppl 3):P2-12-02.
Source: http://breast-cancer-research.com/content/15/1/101
Sylvia Kristel st louis cardinals Steelers Schedule tory burch Al Smith Dinner Herman Melville Books Kyna Treacy
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.